An ever-shifting sales landscape calls for a nimble, responsive sales approach – one often problematic for the behemoth infrastructures of many large pharmaceutical organizations and the experience level of emerging biotechnology firms. As a result, commercial services partners offer a stronger than ever value proposition to the industry.

PDI to Focus on Growing Molecular Diagnostics Business; Plans to Change Name to Interpace Diagnostics Group PDI to receive $25.5 to $32.5 million up front cash payment and a contingent earnout payment Combination Would Create A Global Leader in Healthcare Commercial Services   PARSIPPANY, N.J. & YARDLEY, Pa., Nov. 2, 2015 /PRNewswire/ — PDI, Inc. (Nasdaq: […]

Practical options for emerging specialty pharma By Gerry Melillo, president of commercial services at PDI. The life sciences industry has undeniably entered a new environment for product launches. Not only are the products changing, but those inventing and commercializing the products are transitioning as well. According to a recent research study published by McKinsey, product […]